-
- Giovanna Esposito
- Thoracic Medical Oncology, Istituto Nazionale Tumori, IRCCS “Fondazione G. Pascale”, 80131 Napoli, Italy
-
- Giuliano Palumbo
- Thoracic Medical Oncology, Istituto Nazionale Tumori, IRCCS “Fondazione G. Pascale”, 80131 Napoli, Italy
-
- Guido Carillio
- Department of Oncology and Hematology, Azienda Ospedaliera Pugliese—Ciaccio, 88100 Catanzaro, Italy
-
- Anna Manzo
- Thoracic Medical Oncology, Istituto Nazionale Tumori, IRCCS “Fondazione G. Pascale”, 80131 Napoli, Italy
-
- Agnese Montanino
- Thoracic Medical Oncology, Istituto Nazionale Tumori, IRCCS “Fondazione G. Pascale”, 80131 Napoli, Italy
-
- Vincenzo Sforza
- Thoracic Medical Oncology, Istituto Nazionale Tumori, IRCCS “Fondazione G. Pascale”, 80131 Napoli, Italy
-
- Raffaele Costanzo
- Thoracic Medical Oncology, Istituto Nazionale Tumori, IRCCS “Fondazione G. Pascale”, 80131 Napoli, Italy
-
- Claudia Sandomenico
- Thoracic Medical Oncology, Istituto Nazionale Tumori, IRCCS “Fondazione G. Pascale”, 80131 Napoli, Italy
-
- Carmine La Manna
- Thoracic Surgery, Istituto Nazionale Tumori, “Fondazione G.Pascale”—IRCCS, 80131 Napoli, Italy
-
- Nicola Martucci
- Thoracic Surgery, Istituto Nazionale Tumori, “Fondazione G.Pascale”—IRCCS, 80131 Napoli, Italy
-
- Antonello La Rocca
- Thoracic Surgery, Istituto Nazionale Tumori, “Fondazione G.Pascale”—IRCCS, 80131 Napoli, Italy
-
- Giuseppe De Luca
- Thoracic Surgery, Istituto Nazionale Tumori, “Fondazione G.Pascale”—IRCCS, 80131 Napoli, Italy
-
- Maria Carmela Piccirillo
- Clinical Trials Unit, Istituto Nazionale Tumori, “Fondazione G.Pascale”—IRCCS, 80131 Napoli, Italy
-
- Rossella De Cecio
- Pathology, Istituto Nazionale Tumori, “Fondazione G.Pascale”—IRCCS, 80131 Napoli, Italy
-
- Gerardo Botti
- Scientific Directorate, Istituto Nazionale Tumori, “Fondazione G. Pascale”—IRCCS, 80131 Naples, Italy
-
- Giuseppe Totaro
- Radiotherapy, Istituto Nazionale Tumori, “Fondazione G. Pascale”—IRCCS, 80131 Naples, Italy
-
- Paolo Muto
- Radiotherapy, Istituto Nazionale Tumori, “Fondazione G. Pascale”—IRCCS, 80131 Naples, Italy
-
- Carmine Picone
- Radiology, Istituto Nazionale Tumori, “Fondazione G.Pascale”—IRCCS, 80131 Napoli, Italy
-
- Nicola Normanno
- Cellular Biology and Biotherapy, Istituto Nazionale Tumori, “Fondazione G.Pascale”—IRCCS, 80131 Napoli, Italy
-
- Alessandro Morabito
- Thoracic Medical Oncology, Istituto Nazionale Tumori, IRCCS “Fondazione G. Pascale”, 80131 Napoli, Italy
説明
<jats:p>Small-cell lung cancer (SCLC) is an aggressive tumor type with limited therapeutic options and poor prognosis. Chemotherapy regimens containing platinum represent the cornerstone of treatment for patients with extensive disease, but there has been no real progress for 30 years. The evidence that SCLC is characterized by a high mutational burden led to the development of immune-checkpoint inhibitors as single agents or in combination with chemotherapy. Randomized phase III trials demonstrated that the combination of atezolizumab (IMpower-133) or durvalumab (CASPIAN) with platinum-etoposide chemotherapy improved overall survival of patients with extensive disease. Instead, the KEYNOTE-604 study demonstrated that the addition of pembrolizumab to chemotherapy failed to significantly improve overall survival, but it prolonged progression-free survival. The safety profile of these combinations was similar with the known safety profiles of all single agents and no new adverse events were observed. Nivolumab and pembrolizumab single agents showed anti-tumor activity and acceptable safety profile in Checkmate 032 and KEYNOTE 028/158 trials, respectively, in patients with SCLC after platinum-based therapy and at least one prior line of therapy. Future challenges are the identification predictive biomarkers of response to immunotherapy in SCLC and the definition of the role of immunotherapy in patients with limited stage SCLC, in combination with radiotherapy or with other biological agents.</jats:p>
収録刊行物
-
- Cancers
-
Cancers 12 (9), 2522-, 2020-09-04
MDPI AG